Aletira Therapeutics

Aletira is developing gene therapies that use alternative splicing technology to achieve cell-type selective gene expression, ensuring therapeutic effects target specific cells while avoiding off-target expression. The company's SELEXON technology can be incorporated into various gene therapy platforms, such as adeno-associated viruses (AAV), to improve safety and potency of treatments.